Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
New ticker. Azora Therapeutics, Inc. (DE) now trades under the ticker AZR.
$22MCash on Hand
10.2mo Cash Runway
Follow ADIL by emailGet an email when ADIL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ADIL, unsubscribe in one click. Privacy
📣 What ADIL Says Is Next
first half of 2027 · “Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.” Corporate Highlights”
Company press release, Nov 12, 2026 · SEC filing
first half of 2027 · “Azora expects to advance AT177 into a Phase 1 clinical trial in the first half of 2027.”
Company press release, Oct 28, 2026 · SEC filing
second half of 2027 · “AT177 is currently in IND-enabling studies, with an investigational new drug (“IND”) filing planned for the first half of 2027, initiation of a Phase 1a single- and multiple-ascending-dose (“SAD/MAD”) clinical trial planned to commence in the second half of 2027, followed by a Phase 1b proof-of-concept study in UC patients.”
Company press release, Aug 17, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Financing Azora Therapeutics filed a shelf registration statement to offer up to $250,000,000 in common stock, preferred stock, debt securities, warrants and units from time to time. It also includes a $20,000,000 at-the-market sales agreement with Jefferies LLC, which is part of the $250,000,000 total. Form S-3 · SEC filing
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Reported Q3 2026 results with cash of $22.0 million versus $28.7 million at June 30, 2026, and a Q3 net loss of $64.6 million, or $4.52 per share, including a $57.1 million non-cash warrant liability charge. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Leadership Azora Therapeutics appointed Aida Habtezion, M.D., Paul Hastings and Thomas Soloway to its board effective November 3, 2026, and reconstituted its audit, compensation and governance committees. Non-employee director compensation has not yet been finalized. Form 8-K · SEC filing
Oct 28, 2026 ·
Leadership Azora Therapeutics, formerly Adial Pharmaceuticals, appointed Matthew Davidson, Ph.D. as CEO, replacing Cary J. Claiborne, and Celia Economides as CFO, replacing Vinay Shah, effective October 28, 2026. Julie Saiki, Ph.D. was named Chief Strategy Officer. Form 8-K · SEC filing · Press release
Oct 21, 2026 ·
Amended quarterly report for the period ended Jun 30, 2026 Form 10-Q/A · SEC filing
Oct 16, 2026 ·
Shareholder vote Adial adjourned the 2026 Annual Meeting again, from October 15 to October 26, 2026, for votes on Proposals 3, 4, 5 and 6 while awaiting Nasdaq approval of its Initial Listing Application. The record date remains August 17, 2026. Form 8-K · SEC filing
Oct 2, 2026 ·
Shareholder vote Adial reconvened its 2026 Annual Meeting on October 1, 2026 for Proposals 3, 4, 5 and 6, but the polls remain open after a further adjournment to October 15, 2026, because Nasdaq approval of the Initial Listing Application had not yet been received. Proposals 1, 2, 7 through 12 were already voted on. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2023 · Phase 1 · Results Expected · Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ADIL holds $22M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.5M/quarter from operations,
an estimated runway of 10.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 10 months +30
ATM program on file since Nov 2026 +15
Shelf registration (S-3, Nov 2026) +10
Going-concern doubt in the latest 10-Q +15The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Nov 17, 2026 · Shelf registration with ATM program, up to $20M · S-3
Share count 14,286,311 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ADIL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADIL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.